demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 severe or critically
Oral antidiabetic drugs
DPP-4 inhibitor Abuhasira

15 studies excluded by filtering options 0

5376 Rhee, 2020 0130selection pending
5622 Crouse, 2020 0130selection pending
5623 Bramante, 2020 000selection pending
5624 CORONADO, 2020 000selection pending
5625 Chen, 2020 000selection pending
5626 Luo, 2020 000selection pending
6853 DARE-19, 2021 110risk of bias not avaialble
7084 Fadini, 2020 2200excludednot a RCTrisk of bias not avaialble
7085 Rhee (National Health Insurance Review and Assessment Service of Korea), 2021 1120not a RCTrisk of bias not avaialble
7087 Noh, 2021 0150selection pending
7088 CORONADO, 2020 1130not a RCTrisk of bias not avaialble
7090 Strollo, 2021 2990excludednot a RCTrisk of bias not avaialble
7322 Rhee (National Health Insurance Service database), 2021 1120not a RCTrisk of bias not avaialble
8332 TOGETHER, 0 110risk of bias not avaialble
9252 Guardado-Mendoza, 2022 013selection pending